Image guided drug release from pH-sensitive Ion channel-functionalized stealth liposomes into an in vivo glioblastoma model

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 6, 2015, Pages 1345-1354

  Pacheco Torres, Jesus ^a   Mukherjee, Nobina ^b   Walko, Martin ^d   López Larrubia, Pilar ^a   Ballesteros, Paloma ^c   Cerdan, Sebastian ^a   Kocer, Armagan ^e  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c CSIC   (Spain)

^d P J AFÁRIK UNIVERSITY   (Slovakia)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

C6 glioma tumors; Ion channel engineering; Magnetic resonance spectroscopy and imaging; Mechanosensitive channel of large conductance; pH sensitive liposomes; Triggered drug delivery

Indexed keywords

AMPHIBIOUS VEHICLES; DISEASES; IONS; MAGNETIC LEVITATION VEHICLES; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; MEDICAL NANOTECHNOLOGY; PH SENSORS; TUMORS;

DRUG DELIVERY SYSTEM; DRUG DELIVERY VEHICLES; ENVIRONMENTAL STIMULI; ION CHANNEL; MECHANOSENSITIVE CHANNEL; PH-SENSITIVE LIPOSOMES; STEALTH LIPOSOMES; TUMOR MICROENVIRONMENT;

LIPOSOMES;

ANTINEOPLASTIC AGENT; FLUORESCENT DYE; GADOLINIUM PENTETATE MEGLUMINE; ION CHANNEL; NANOCARRIER; PROTEOLIPOSOME; DRUG CARRIER; LIPOSOME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG RELEASE; DRUG SELECTIVITY; DRUG SENSITIVITY; ESCHERICHIA COLI; GLIOBLASTOMA; IMAGE GUIDED DRUG RELEASE; IMAGING SOFTWARE; IN VITRO STUDY; IN VIVO STUDY; LIPID BILAYER; LIPOSOMAL DELIVERY; MALE; MOUSE; MOUSE MODEL; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; PRE-CLINICAL IMAGING DEVICE; PROTEIN ISOLATION; PROTON NUCLEAR MAGNETIC RESONANCE; RELAXATION TIME; SENSITIVITY ANALYSIS; SYNTHESIS; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; PATHOLOGY;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; GLIOBLASTOMA; HYDROGEN-ION CONCENTRATION; ION CHANNELS; LIPOSOMES; MALE; MICE; MICE, INBRED C57BL;

EID: 84937145710     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.03.014     Document Type: Article

References (44)

1. Pinedo H.M., Giaccone G. Chemother Lancet 1997, 349(Suppl. 2):SII7-SII9.
2. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
3. Park J.H., von Maltzahn G., Xu M.J., Fogal V., Kotamraju V.R., Ruoslahti E., et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A 2010, 107:981-986.
4. Wojtkowiak J.W., Verduzco D., Schramm K.J., Gillies R.J. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm 2011, 8:2032-2038.
5. Fojo T., Coley H.M. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin Breast Cancer 2007, 7:749-756.
6. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007, 446:749-757.
7. Egusquiaguirre S.P., Igartua M., Hernandez R.M., Pedraz J.L. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 2012, 14:83-93.
8. O'Connor R. The pharmacology of cancer resistance. Anticancer Res 2007, 27:1267-1272.
9. Garcia-Martin M.L., Herigault G., Remy C., Farion R., Ballesteros P., Coles J.A., et al. Mapping extracellular pH in rat brain gliomas in vivo by 1H magnetic resonance spectroscopic imaging: comparison with maps of metabolites. Cancer Res 2001, 61:6524-6531.
10. Gatenby R.A., Gawlinski E.T., Gmitro A.F., Kaylor B., Gillies R.J. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006, 66:5216-5223.
11. Gatenby R.A., Gillies R.J. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008, 8:56-61.
12. Kallinowski F., Vaupel P. pH distributions in spontaneous and isotransplanted rat tumours. Br J Cancer 1988, 58:314-321.
13. Stubbs M., McSheehy P.M., Griffiths J.R. Causes and consequences of acidic pH in tumors: a magnetic resonance study. Adv Enzym Regul 1999, 39:13-30.
14. Vaupel P. Vascularization, blood flow, oxygenation, tissue pH, and bioenergetic status of human breast cancer. Adv Exp Med Biol 1997, 411:243-254.
15. Wike-Hooley J.L., Haveman J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984, 2:343-366.
16. Wike-Hooley J.L., Van der Zee J., van Rhoon G.C., Van den Berg A.P., Reinhold H.S. Human tumour pH changes following hyperthermia and radiation therapy. Eur J Cancer Clin Oncol 1984, 20:619-623.
17. Bailey K.M., Wojtkowiak J.W., Hashim A.I., Gillies R.J. Targeting the metabolic microenvironment of tumors. Adv Pharmacol 2012, 65:63-107.
18. Gerweck L.E., Kozin S.V., Stocks S.J. The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells. Br J Cancer 1999, 79:838-842.
19. Raghunand N., He X., van Sluis R., Mahoney B., Baggett B., Taylor C.W., et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999, 80:1005-1011.
20. Yatvin M.B., Kreutz W., Horwitz B.A., Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science 1980, 210:1253-1255.
21. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998, 16:2445-2451.
22. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investig 2001, 19:424-436.
23. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
24. Bae K.H., Chung H.J., Park T.G. Nanomaterials for cancer therapy and imaging. Mol Cells 2011, 31:295-302.
25. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
26. Drummond D.C., Zignani M., Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 2000, 39:409-460.
27. Lee E.S., Gao Z., Bae Y.H. Recent progress in tumor pH targeting nanotechnology. J Control Release 2008, 132:164-170.
28. Drummond D.C., Noble C.O., Hayes M.E., Park J.W., Kirpotin D.B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008, 97:4696-4740.
29. Kocer A., Walko M., Bulten E., Halza E., Feringa B.L., Meijberg W. Rationally designed chemical modulators convert a bacterial channel protein into a pH-sensory valve. Angew Chem Int Ed Engl 2006, 45:3126-3130.
30. Birkner J.P., Poolman B., Kocer A. Hydrophobic gating of mechanosensitive channel of large conductance evidenced by single-subunit resolution. Proc Natl Acad Sci U S A 2012, 109:12944-12949.
31. Yoshimura K., Batiza A., Kung C. Chemically charging the pore constriction opens the mechanosensitive channel MscL. Biophys J 2001, 80:2198-2206.
32. Ou X., Blount P., Hoffman R.J., Kung C. One face of a transmembrane helix is crucial in mechanosensitive channel gating. Proc Natl Acad Sci U S A 1998, 95:11471-11475.
33. Kocer A. A remote controlled valve in liposomes for triggered liposomal release. J Liposome Res 2007, 17:219-225.
34. Blount P., Sukharev S.I., Schroeder M.J., Nagle S.K., Kung C. Single residue substitutions that change the gating properties of a mechanosensitive channel in Escherichia coli. Proc Natl Acad Sci U S A 1996, 93:11652-11657.
35. Guzman L.M., Belin D., Carson M.J., Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol 1995, 177:4121-4130.
36. Kocer A., Walko M., Feringa B.L. Synthesis and utilization of reversible and irreversible light-activated nanovalves derived from the channel protein MscL. Nat Protoc 2007, 2:1426-1437.
37. Provent P., Benito M., Hiba B., Farion R., Lopez-Larrubia P., Ballesteros P., et al. Serial in vivo spectroscopic nuclear magnetic resonance imaging of lactate and extracellular pH in rat gliomas shows redistribution of protons away from sites of glycolysis. Cancer Res 2007, 67:7638-7645.
38. Hennig J., Friedburg H. Clinical applications and methodological developments of the RARE technique. Magn Reson Imaging 1988, 6:391-395.
39. Hennig J., Nauerth A., Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 1986, 3:823-833.
40. de Graaf R.A., Brown P.B., Rothman D.L., Behar K.L. Natural abundance (17)O NMR spectroscopy of rat brain in vivo. J Magn Reson 2008, 193:63-67.
41. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25years of image analysis. Nat Methods 2012, 9:671-675.
42. Pacheco-Torres J., Calle D., Lizarbe B., Negri V., Ubide C., Fayos R., et al. Environmentally sensitive paramagnetic and diamagnetic contrast agents for nuclear magnetic resonance imaging and spectroscopy. Curr Top Med Chem 2011, 11:115-130.
43. Yuba E., Tajima N., Yoshizaki Y., Harada A., Hayashi H., Kono K. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Biomaterials 2014, 35:3091-3101.
44. Tzeng S.Y., Green J.J. Therapeuric nanomedicine for brain cancer. Ther Deliv 2013, 4:687-704.